Genişlemiş spektrumlu beta-laktamaz üreten escherichia coli izolatlarında tigesiklin duyarlılığının belirlenmesi
Küçük Resim Yok
Tarih
2013
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Escherichia coli dünyada en sık enfeksiyon yapan patojenlerden biridir. E. coli suşları toplum ve hastane kaynaklı önemli enfeksiyonlara yol açabilmektedir. Kolay direnç kazanması tedavide zorluklara neden olmaktadır. Genişlemiş spektrumlu beta -laktamaz (GSBL) üreten suşlarda tedavi seçenekleri azalabilmektedir. Araştırmacılar tedavi seçeneklerinin sınırlı kalmasından dolayı alternatif arayışlarına d evam etmektedir. Bir glisilsiklin türevi olan tigesiklin (GAR - 936) son yıllarda kullanıma giren bir ajandır. Bu çalışmada Abant İzzet Baysal Üniversitesi Tıp Fakültesi mikrobiyoloji laboratuvarında çeşitli klinik örneklerden elde edilen GSBL üreten E. coli izolatlarında tigesikline duyarlılık oranının in vitro olarak araştırılması amaçlanmıştır. Yöntem: : Toplam 100 GSBL üreten E. coli izolatına için tigesiklin minimum inhibitör konsantrasyon (MİK) değerleri sıvı mikrodilüsyon yöntemiyle belirlenmiştir. Bulgular : Tigesiklinin izolatlara karşı MİK değerleri 0,125 -4 µg/ml aralığında bulunmuş, buna göre izolatların 97’si (%97) tigesikline duyarlı, üçü (%3) ise orta duyarlı bulunmuştur. MİK50 değeri 0,5 µg/ml, MİK90 değeri ise 2 µg/ml olarak saptanmıştır. Sonuç : Çalışmamızda elde edilen bulgular, hastanemizde GSBL üreten E. coli nedenli enfeksiyonların tedavisinde tigesiklinin halen uygun bir alternatif olduğunu göstermektedir.
Objective : Escherichia coli is one of the most common pathogens causing infection in the world. E. coli strains can lead to emergent community- and hospital -acquired infections. Treatment of ESBL producing E. coli infections encounter difficulties due to the resistance which is easily acquired. Treatment options may decrease particularly in the strains producing expended -spectrum beta -lactamase (ESBL). R esearchers continue to search for an alternative due to the limited treatment options. Tigecycline (GAR -936), a derivative of glycylcycline, is an agent accepted for the usage for treatment in recent years. In this study, it was aimed to investigate the in vitro susceptibility rate of ESBL producing E. coli strains isolated from various clinical specimens in microbiology laboratory of Abant Izzet Baysal University Faculty of Medicine to tigecycline. Method : Minimum inhibitory concentration (MIC) of tigecycline were detemined with broth microdilution method for a total of 100 ESBL producing E. coli isolates. Results : MIC values of tigecycline to the isolates were found between a range of 0.125 -4 µg/ml, according to this 97 (97%) of the isolates were determined as susceptible and 3 (3%) were found as intermediate to tigecycline. The MIC50 value was found 0.5 µg/ml and MIC90 was 2 µg/ml. Conclusion : The findings obtained from our study shows that tigecycline is still an appropriate alternative in trea tment of infections caused by ESBL producing E. coli in our hospital.
Objective : Escherichia coli is one of the most common pathogens causing infection in the world. E. coli strains can lead to emergent community- and hospital -acquired infections. Treatment of ESBL producing E. coli infections encounter difficulties due to the resistance which is easily acquired. Treatment options may decrease particularly in the strains producing expended -spectrum beta -lactamase (ESBL). R esearchers continue to search for an alternative due to the limited treatment options. Tigecycline (GAR -936), a derivative of glycylcycline, is an agent accepted for the usage for treatment in recent years. In this study, it was aimed to investigate the in vitro susceptibility rate of ESBL producing E. coli strains isolated from various clinical specimens in microbiology laboratory of Abant Izzet Baysal University Faculty of Medicine to tigecycline. Method : Minimum inhibitory concentration (MIC) of tigecycline were detemined with broth microdilution method for a total of 100 ESBL producing E. coli isolates. Results : MIC values of tigecycline to the isolates were found between a range of 0.125 -4 µg/ml, according to this 97 (97%) of the isolates were determined as susceptible and 3 (3%) were found as intermediate to tigecycline. The MIC50 value was found 0.5 µg/ml and MIC90 was 2 µg/ml. Conclusion : The findings obtained from our study shows that tigecycline is still an appropriate alternative in trea tment of infections caused by ESBL producing E. coli in our hospital.
Açıklama
Anahtar Kelimeler
Biyoteknoloji ve Uygulamalı Mikrobiyoloji, Tıbbi İnformatik, Mikrobiyoloji, Farmakoloji ve Eczacılık
Kaynak
Abant Tıp Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
2
Sayı
2
